Since TOP2A amplified tumor cells tend to be sensitive to topo-II inhibitor therapy while TOP2A deleted tumor cells tend to be resistant to anthracycline chemotherapy [21], the overall response of a given breast cancer case will depend on the relative proportions of the 2 cell types. This evidence concerns the gene TOP2A and neoplasm.